Hemogenyx PharmaceuticalsHOPHF 31 EV-to-FCF is -15.36 as of Jul. 07, 2026. GuruFocus rates HOPHF with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 329 Biotechnology companies, Hemogenyx Pharmaceuticals ranks worse than 303951.06% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Hemogenyx Pharmaceuticals's Enterprise Value is $72.03 Mil.
Hemogenyx Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.69 Mil. Therefore, Hemogenyx Pharmaceuticals's EV-to-FCF for today is -15.36.
The historical rank and industry rank for Hemogenyx Pharmaceuticals's EV-to-FCF or its related term are showing as below:
HOPHF'
s EV-to-FCF Range Over the Past 10 Years
Min: -15.81 Med: 0 Max: 0
Current: -15.81
HOPHF's EV-to-FCF is ranked worse than 100% of 329
companies
in the Biotechnology industry
Industry Median: 16.38
vs HOPHF: -15.81
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hemogenyx Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Hemogenyx Pharmaceuticals's share price for today is $2.33.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hemogenyx Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.974.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Hemogenyx Pharmaceuticals EV-to-FCF Related Terms
Hemogenyx Pharmaceuticals EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hemogenyx Pharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Hemogenyx Pharmaceuticals's EV-to-FCF falls into.
Hemogenyx Pharmaceuticals's current Enterprise Value is $72.03 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hemogenyx Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.69 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hemogenyx Pharmaceuticals (HOPHF) has a EV-to-FCF of -15.36 as of Jul. 07, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hemogenyx Pharmaceuticals and its competitors. According to the industry distribution chart, Hemogenyx Pharmaceuticals ranks #999999 out of 329 companies in the Biotechnology industry.
Is Hemogenyx Pharmaceuticals' EV-to-FCF too high?
Hemogenyx Pharmaceuticals' current EV-to-FCF is -15.36. Based on the distribution chart, Hemogenyx Pharmaceuticals ranks #999999 out of 329 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Hemogenyx Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Hemogenyx Pharmaceuticals' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hemogenyx Pharmaceuticals ranks #999999 out of 329 companies for EV-to-FCF. This places Hemogenyx Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 16.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.38, based on 329 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hemogenyx Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hemogenyx Pharmaceuticals's current EV-to-FCF is -15.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemogenyx Pharmaceuticals stock overvalued right now?
Hemogenyx Pharmaceuticals (HOPHF) has a current EV-to-FCF of -15.36. The current EV-to-FCF is -15.36. Hemogenyx Pharmaceuticals' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Hemogenyx Pharmaceuticals (HOPHF), the current EV-to-FCF is -15.36 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hemogenyx Pharmaceuticals PLC is clinical-stage biotechnology focused on the discovery, development and commercialisation of treatments relating to the treatment of blood cancers, certain solid cancers, autoimmune diseases, and viral infections. The products under development are designed to address a range of problems that occur with current standard of care treatments. The Group has one reportable segment, the discovery, development, and commercialisation of treatments relating to blood and immune system disorders and viral infections, and administrative functions in the United Kingdom. It has its presence in United Kingdom; and United States.
31GF Score
Get the complete analysis for HOPHF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOPHF has been successfully added to your 
